SAGE - Sage Therapeutics, Inc.
165.35 0.00 (0.00%)
After hours: 5:20PM EDT
| Previous Close | 159.79 |
| Open | 159.60 |
| Bid | 161.00 x 1200 |
| Ask | 177.50 x 900 |
| Day's Range | 158.37 - 166.35 |
| 52 Week Range | 79.88 - 193.56 |
| Volume | 249,337 |
| Avg. Volume | 366,866 |
| Market Cap | 8.541B |
| Beta (3Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.68 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 202.50 |
- Business Wire
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sage Therapeutics, Inc. (SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on September 3, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 12,300 shares of its common stock, and 2,050 performance restricted stock units (PSUs) to four new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Business Wire
Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder
Sage Therapeutics (SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that the New England Journal of Medicine (NEJM) published full results from the double-blind, randomized, placebo-controlled Phase 2 study evaluating SAGE-217 as a treatment for major depressive disorder (MDD). In the study, SAGE-217, taken orally, once daily, showed a rapid, statistically significant reduction in Hamilton Rating Scale for Depression (HAM-D) total scores versus placebo beginning the morning following the first dose (Day 2) and sustained through the primary endpoint of Day 15 (-7.1 difference, p
- Business Wire
Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
Sage Therapeutics (SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 11:05 a.m. EDT in New York, NY. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
- Thomson Reuters StreetEvents
Edited Transcript of SAGE earnings conference call or presentation 6-Aug-19 12:00pm GMT
Q2 2019 SAGE Therapeutics Inc Earnings Call
- Business Wire
Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ injection CIV, the first treatment specifically indicated for postpartum depression, commercially launched in the U.S. in late-June, with first patients tre
- Business Wire
Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
Sage Therapeutics (SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, in New York, NY. Steve Kanes, M.D., chief medical officer of Sage, will be a featured speaker on the panel, Overcoming Challenges in CNS Drug Development, at 11:30 a.m. EDT. A live webcast of the panel can be accessed on the investor page of Sage's website at investor.sagerx.com.
- Zacks
Earnings Preview: Sage Therapeutics (SAGE) Q2 Earnings Expected to Decline
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
Wall Street is not sold on the latest clinical results.
- Markit
See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding SAGE is favorable, with net inflows of $6.08 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.
Is Sage Therapeutics's (NASDAQ:SAGE) 287% Share Price Increase Well Justified?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
- Business Wire
Sage Therapeutics to Host “Sage FutureCast” Webcast
Event will provide an R&D and portfolio review across the depression, neurology and neuropsychiatric franchises
- Insider Monkey
Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
- Business Wire
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 8:40 a.m. EST in New York, NY. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
- American City Business Journals
Why Sage Therapeutics' new Brier Creek center came at the perfect time
On the same day as it cut the ribbon on its new Triangle patient support center, a Cambridge pharmaceutical company overcame the last regulation hurdle to bring its first-in-kind treatment to postpartum depression patients.
- Business Wire
Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
Sage Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Drug Enforcement Administration (DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of the Controlled Substances Act. ZULRESSO, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, is the first and only treatment specifically approved for postpartum depression (PPD), the most common medical complication of childbirth. With this decision, the product label for ZULRESSO will be finalized.
- American City Business Journals
Life sciences VC firm Third Rock raises $770M in its largest round ever
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
